Clinical Challenges and Complications of IBD

Miguel D Regueiro, MD; Jason Swoger, MD MPH

Chapter 16: Anti-Tumor Necrosis Factor Therapy (continued)

A. Hillary Steinhart, MD, MSc, FRCP(C)

Safety and Toxicity The development of anti-tumor necrosis factor-alpha (TNF-α)–based therapies for the treatment of Crohn’s disease (CD) and ulcerative colitis (UC) has been a major advance in the management of these conditions. Large randomized controlled trials have demonstrated efficacy in both CD and UC, leading to their approval for use in both conditions in many countries. Just as important as the demonstration of efficacy, these trials with few exceptions found that the use of anti-TNF-α therapy was not associated with increased risk of adverse effects or…